News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amylin Pharmaceuticals, Inc. (AMLN) Said to Have Spurned $3.5 Billion Bristol-Myers Squibb Company (BMY) Bid


3/28/2012 8:10:59 AM

Amylin Pharmaceuticals Inc. (AMLN), the maker of the diabetes drug Bydureon, rejected a $3.5 billion unsolicited takeover bid from Bristol-Myers Squibb Co. (BMY) earlier this year, according to two people with knowledge of the matter. Bristol-Myers proposed an acquisition at $22 a share in a letter to Amylin, which the board turned down last month, said the people, who declined to be identified because the approach was private. The price is 43 percent more than Amylin’s closing stock price of $15.39 yesterday. The $3.5 billion figure, based on 160.8 million Amylin shares outstanding, excludes debt.

Read at Reuters
Read at Bloomberg
Read at SF Gate
Read at Barron's Online
Read at Fox News


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES